Month: April 2020

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

Written by Customer Service on April 20, 2020. Posted in Public Companies.

Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 diseaseTrial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19 Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials...

EssilorLuxottica: EssilorLuxottica to Prepare for Recovery by Preserving Cash and Supporting Employees

Written by Customer Service on April 20, 2020. Posted in Dividend Reports And Estimates.

EssilorLuxottica to Prepare for Recoveryby Preserving Cash and Supporting EmployeesCharenton-le-Pont, France (April 20, 2020 – 7:00am) – EssilorLuxottica announces today further measures to respond to the COVID-19 pandemic and prepare the Company for the recovery to come.Prescription and optical activities, which account for about 70% of Company revenue, are driven by structural worldwide needs for better vision. Experience from previous economic downturns suggests that prescription purchases will be delayed during the crisis, but not cancelled. Thanks to its mission to help people see more, be more and live life to its fullest, the Company is fully equipped to meet the resilient pent-up demand which is likely to materialise when the economy stabilizes.With this long-term view, EssilorLuxottica aims to manage a temporary decline in activity...

EssilorLuxottica : EssilorLuxottica prépare la reprise en préservant sa trésorerie et en soutenant ses employés

Written by Customer Service on April 20, 2020. Posted in Dividend Reports And Estimates.

EssilorLuxottica prépare la repriseen préservant sa trésorerie et en soutenant ses employésCharenton-le-Pont, France (le 20 avril 2020 – 7h00) – EssilorLuxottica annonce ce jour de nouvelles mesures pour répondre à l’épidémie de COVID-19 et préparer le groupe à la reprise à venir.Les activités de prescription et d’optique ophtalmique, qui représentent environ 70 % du chiffre d’affaires consolidé, sont étayées par des besoins structurels et mondiaux d’amélioration de la vision. L’expérience des précédents ralentissements économiques indique que les achats de prescription peuvent être reportés durant les crises mais non pas annulés. Grâce à sa mission d’aider chacun à mieux voir, mieux être pour profiter pleinement de la vie, le groupe est parfaitement à même d’honorer le rattrapage de demande amené à se matérialiser lorsque l’économie...

AMG Advanced Metallurgical Group N.V. Withdraws 2020 Earnings Target and Announces First Quarter 2020 Earnings Call and Webcast Date Annual General Meeting to be Held May 6, 2020

Written by Customer Service on April 20, 2020. Posted in Public Companies.

Amsterdam, 20 April 2020 (Regulated Information) — AMG Advanced Metallurgical Group N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) provides an update on its 2020 earnings target and announces the First Quarter 2020 Earnings Call timing.Given the difficulty of projecting earnings for the remainder of the year due to COVID-19 effects on our customers, AMG has decided to withdraw its earnings guidance for 2020. A new target will be announced once the global industrial economy begins to stabilize.AMG’s operations remain robust, and its employee base is healthy, with only one reported case of COVID-19. Nonetheless, given the potential strains on our customer base, predicting demand fluctuations is difficult.AMG’s balance sheet is sound and the Company enjoys significant liquidity. AMG has approximately $200 million in cash, $170 million of...

MDxHealth to Receive $2.3 million “Paycheck Protection Program” Loan Under the U.S. CARES Act

Written by Customer Service on April 20, 2020. Posted in Public Companies.

NEWS RELEASEIRVINE, CA, and HERSTAL, BELGIUM – April 20, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that its U.S. subsidiary, MDxHealth Inc., has entered into a “Paycheck Protection Program” (PPP) loan with the U.S. Small Business Administration (SBA) in the amount of $2.3 million as part of the U.S Coronavirus Aid, Relief, and Economic Security (CARES) Act. These PPP loans are aimed at helping small businesses in the U.S. keep their workers on payroll by providing loans that are partially forgivable.The loan has a term of two years and carries an interest rate of 1.0% per year. Payments on the loan are deferred for the first six months following disbursement of the loan, with principal and interest payments beginning on the seventh month. Interest on the loan...

Philips delivers Q1 sales of EUR 4.2 billion, with 2% comparable sales decrease; income from continuing operations amounted to EUR 42 million and Adjusted EBITA margin was 5.9%

Written by Customer Service on April 20, 2020. Posted in Public Companies.

April 20, 2020“The start of 2020 was marked by the COVID-19 outbreak, and we have mobilized our resources since January to address this unprecedented challenge. At Philips, we are focused on our triple duty of care: meeting critical customer needs, safeguarding the health and safety of our employees, and ensuring business continuity. I am very proud of the commitment, hard work and resourcefulness of our employees to keep Philips fully functioning, and I would like to thank them for that.COVID-19 significantly affected our results in this quarter. There was increased demand for our professional healthcare products and solutions, with comparable sales and order intake growth for the Connected Care and Diagnosis & Treatment businesses. Comparable order intake grew 23%, most notably in diagnostic imaging, hospital ventilators, and patient...

Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia

Written by Customer Service on April 20, 2020. Posted in Public Companies.

• Idorsia to host an investor webcast to discuss the first Phase 3 results today at 14:00hrs CESTAllschwil, Switzerland – April 20, 2020Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the first pivotal Phase 3 study investigating 25 and 50 mg doses of its dual orexin receptor antagonist, daridorexant, in 930 adult and elderly patients (39.1% ≥ 65 years) with insomnia. The study demonstrated efficacy of treatment with daridorexant on objective and subjective sleep parameters and daytime performance with no residual effect in the morning, and no evidence of rebound or withdrawal symptoms upon treatment discontinuation.Daridorexant at both 25 and 50 mg significantly improved sleep onset and sleep maintenance as measured objectively in a sleep lab by polysomnography. Daridorexant also significantly improved subjective...

Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia

Written by Customer Service on April 20, 2020. Posted in Public Companies.

US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time

Written by Customer Service on April 20, 2020. Posted in Public Companies.

Reduces infusion time to 2 hours from the current 3.5 hours for patients with relapsing or primary progressive multiple sclerosis, if approvedApplications are based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the currently approved OCREVUS dosing regimen Basel, 20 April 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and the European Medicines Agency (EMA) has validated the application for a two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly for relapsing or primary progressive multiple sclerosis (MS).AttachmentRoche_mediarelease Ocrevus_20042020 _EN

IMCD reports 11% EBITA growth in the first three months of 2020

Written by Customer Service on April 20, 2020. Posted in Public Companies.

Rotterdam, The Netherlands (20 April 2020) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and food ingredients, today announces its first three months 2020 results and announces that its Annual General Meeting of Shareholders will be held on 30 June 2020. The AGM agenda will be published on 19 May 2020. HIGHLIGHTSGross profit growth of 12% to EUR 176.4 million (+12% on a constant currency basis)Operating EBITA increase of 11% to EUR 70.9 million (+11% on a constant currency basis)Net result before amortisation and non-recurring items increase of 13% to EUR 50.2 million (+13% on a constant currency basis)Cash earnings per share increased by 13% to EUR 0.94 (first three months of 2019: EUR 0.83)Piet van der Slikke, CEO: “IMCD’s first quarter results were strong with an operating EBITA...

Month: April 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals